Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · March 16, 2023

Very Low LDL-C Levels Achieved by Statin and Alirocumab Therapy Are Associated With Cardiovascular Risk Reduction

European Heart Journal


Additional Info

European Heart Journal
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Eur Heart J 2023 Mar 05;[EPub Ahead of Print], GG Schwartz, M Szarek, DL Bhatt, VA Bittner, M Bujas-Bobanovic, R Diaz, S Fazio, Z Fras, SG Goodman, RA Harrington, JW Jukema, G Manvelian, R Pordy, KK Ray, M Scemama, HD White, PG Steg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading